Most-cited papers on solid tumor extend metabolic neuroblastoma

Ranked by citation count via OpenAlex. Citations update on a rolling basis; list regenerates every 24h.

1. Extended phase I evaluation of vincristine, irinotecan, temozolomide, and antibiotic in children with refractory solid tumors

   2010 · Pediatric Blood & Cancer · McNall‐Knapp, Rene, Williams, Cydni N., Reeves, Elaine N. et al.

   41 cited

2. 453O DS-7300 (B7-H3 DXd antibody-drug conjugate [ADC]) shows durable antitumor activity in advanced solid tumors: Extended follow-up of a phase I/II study

   2022 · Annals of Oncology · Doi, T., Patel, Minesh, Falchook, G.S. et al.

   38 cited

3. The “Fingerprint” of Cancer Extends Beyond Solid Tumor Boundaries: Assessment With a Novel Ultrasound Imaging Approach

   2015 · IEEE Transactions on Biomedical Engineering · Rao, Sneha R., Shelton, Sarah E., Dayton, Paul A.

   37 cited

4. Phase I LITESPARK-001 study of belzutifan for advanced solid tumors: Extended 41-month follow-up in the clear cell renal cell carcinoma cohort

   2023 · European Journal of Cancer · Jonasch, Eric, Bauer, Todd M., Papadopoulos, Kyriakos P. et al.

   25 cited

5. Safety and pharmacokinetics of veliparib extended‐release in patients with advanced solid tumors: a phase I study

   2018 · Cancer Medicine · Werner, Theresa L., Sachdev, Jasgit C., Swisher, Elizabeth M. et al.

   20 cited

6. Definitive Local Consolidative Therapy for Oligometastatic Solid Tumors: Results From the Lead-in Phase of the Randomized Basket Trial EXTEND

   2022 · International Journal of Radiation Oncology*Biology*Physics · Sherry, Alexander D., Bathala, Tharakeswara, Liu, Suyu et al.

   20 cited

7. Chimeric Antigen Receptor T Cells: Extending Translation from Liquid to Solid Tumors

   2018 · Human Gene Therapy · Morgan, Michael, Schambach, Axel

   15 cited

8. Targeting regulatory T cells by E7777 enhances CD8 T-cell–mediated anti-tumor activity and extends survival benefit of anti-PD-1 in solid tumor models

   2023 · Frontiers in Immunology · Mahdi, Haider, Woodall-Jappe, Mary, Singh, Preeti et al.

   11 cited

9. A real-world study on the safety of the extended dosing schedule for nivolumab and pembrolizumab in patients with solid tumors

   2022 · International Immunopharmacology · Morimoto, Kenji, Yamada, Tadaaki, Morimoto, Yoshie et al.

   8 cited

10. Clinical and Molecular Findings of Infections Caused by Extended-Spectrum β-Lactamase-Producing <i>Enterobacterales</i> in Patients with Solid Tumors: A Single-Center Study

    2021 · Microbial Drug Resistance · Szymankiewicz, Maria, Stefaniuk, Elżbieta, Baraniak, Anna et al.

    7 cited

11. Extending the chimeric receptor-based T-cell targeting strategy to solid tumors

    2013 · OncoImmunology · Rössig, Claudia

    6 cited